Shots:

• The 1st patient has been dosed in the P-III (DESTINY-Lung04) trial to evaluate Enhertu (5.4 mg/kg) vs SoC in a ratio (1:1) in 264 patients with HER2 mutant unresectable, LA or metastatic non-sq. NSCLC at multiple sites across Asia, EU & North America. The therapy is being jointly developed with AstraZeneca
• The 1EP is PFS as assessed by BICR & 2EPs include OS, investigator-assessed PFS, ORR & DoR as assessed by BICR & investigator & also evaluates PK, tolerability, immunogenicity & safety
• Daiichi Sankyo & AstraZeneca collaborated to jointly develop & commercialize Enhertu & Dato-DXd Ex- Japan where Daiichi Sankyo got exclusive rights & will lead the manufacturing & supply of products

Ref: Businesswire | Image: Daiichi Sankyo